Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

14.46 1.05

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.31

Max

14.72

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+104.01% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	130M 1.3B
Vorige openingsprijs	13.41
Vorige sluitingsprijs	14.46

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2026, 23:56 UTC

Mettler-Toledo shares are higher in after-market trading, reflecting a broader market rebound amid gains from major stocks like Tesla and UnitedHealth.

21 aug 2026, 23:56 UTC

Constellation Energy shares are higher in after-market hours, reflecting broader gains among major stocks. No specific news was identified for the price movement.

21 aug 2026, 23:56 UTC

Virtu Financial Inc. shares are higher in after-market trading, following a broader market rebound despite earlier pressures from rising crude oil prices and bond yields.

21 aug 2026, 23:56 UTC

TE Connectivity Ltd. shares declined in after-market trading, remaining near the lower end of their one-month range and below the 20-day moving average.

21 aug 2026, 23:56 UTC

APA Corp. is trading higher in after-market hours, reflecting broader market strength despite a recent yield-driven selloff. No specific news was identified.

21 aug 2026, 23:56 UTC

Social Media

Options trading for Costco includes a notable $950 call option that rose from $0.99 to $2.70. Shares remain roughly flat in after-market trading.

21 aug 2026, 23:56 UTC

MercadoLibre Inc. is higher in after-market hours, reflecting routine performance amid broader market gains following earlier pressure from rising crude oil prices and bond yields.

21 aug 2026, 23:56 UTC

NiSource shares are higher in after-market trading, reflecting broader market gains following a recent selloff. No specific company news was identified.

21 aug 2026, 23:56 UTC

OPKO Health Inc. shares declined in after-market trading, despite gains in major stocks as the broader market rebounded from earlier pressures.

21 aug 2026, 23:56 UTC

Agilent Technologies Inc shares are lower in after-market hours, diverging from broader market gains. No specific news was identified to explain the decline.

21 aug 2026, 23:56 UTC

Devon Energy Corp shows little change in after-market trading, remaining near unchanged since Friday's close and positioned 8.63% above its 20-day moving average.

21 aug 2026, 23:56 UTC

Ginkgo Bioworks Holdings Inc is higher in after-market trading amid a broader market rebound, despite no specific company news identified.

21 aug 2026, 23:56 UTC

Equitable Holdings Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

21 aug 2026, 23:56 UTC

Correlated Moves

US Bancorp shares are higher in after-hours trading, reflecting positive sentiment in the banking sector amid a broader market rebound.

21 aug 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

21 aug 2026, 23:56 UTC

Macro News

ETF Constituents

Vanguard Information Technology ETF rises in after-market hours, supported by gains in key holdings like NVIDIA, Apple, and Intuit amid broader market recovery.

21 aug 2026, 23:56 UTC

Century Aluminum Co. shares gained after-market, recovering from an earlier dip. The movement reflects broader market trends amid rising crude oil prices and bond yields.

21 aug 2026, 23:56 UTC

Correlated Moves

Duke Energy shares rose in after-market trading, reflecting broader market gains despite remaining below the 20-day moving average after four consecutive lower sessions.

21 aug 2026, 23:56 UTC

B&G Foods Inc. traded roughly flat during after-market hours with no specific news. The broader market rebounded, but the stock remains near its one-month low.

21 aug 2026, 23:52 UTC

South Africa's Balance of Trade Report on August 28, 2026: Analysts Anticipate Continued Surplus Amid Global Economic Instability.

21 aug 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Release on August 25, 2026, Expected to Show Modest Growth Amid Mixed Housing Market Sentiment and Rising Inflation Concerns.

21 aug 2026, 23:52 UTC

US GDP Price Index QoQ 2nd Estimate for Q2, forecasted at a 0.063% increase, set to release on August 26 amid rising optimism in economic indicators and inflation concerns.

21 aug 2026, 23:52 UTC

XRP is trading higher during Friday's session, supported by a broader cryptocurrency rally and a U.S. Treasury announcement on bond buyback operations.

21 aug 2026, 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, reflecting a notable retracement despite being above the 20-day moving average.

21 aug 2026, 23:51 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.

21 aug 2026, 23:51 UTC

Par Pacific Holdings Inc. shares are lower in after-market hours, continuing a trend within the broader context of its one-month trading range.

21 aug 2026, 23:51 UTC

Paylocity Holding Corp shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

21 aug 2026, 23:51 UTC

Shift4 Payments Inc is trading higher in after-market hours, supported by a rally in cryptocurrencies that benefits crypto-exposed equities.

21 aug 2026, 23:51 UTC

Coca-Cola Europacific Partners PLC shares are higher in after-market hours, recovering from an earlier dip amid broader market trends and a cryptocurrency rally.

21 aug 2026, 23:51 UTC

Kirby Corp shares are higher in after-market trading, reflecting a strong performance that exceeds the 20-day moving average. No specific news was identified.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

104.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 104.01%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.